Human Reproduction, Vol. 14, No. 7, 1903-1907,
July 1999
© 1999 European Society of Human Reproduction and Embryology
Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool
Department of Obstetrics and Gynaecology, Hadassah University Hospital, PO Box 12000, Jerusalem, Israel, Institute for reproduction and development, Monash Medical Centre, Melbourne, Australia and Division of Obstetrics and Gynaecology, University of Leeds, West Yorkshire, UK
Studies have shown that ovarian failure is a common side-effect of chemotherapy treatment; however, continuation of regular menses post-treatment does not necessarily imply that the ovaries have escaped damage. This animal study measures directly the primordial follicle (PMF) loss following exposure to chemotherapy and evaluates reproductive outcome following significant destruction of the PMF population. Inbred Balb/c mice aged 5–6 weeks were administered different doses of an alkylating agent, cyclophosphamide, and the total number of PMF remaining in both ovaries was counted. Results show that cyclophosphamide causes PMF destruction in proportion to increasing dose (P = 0.0001). Reproductive performance was assessed after exposure to 75 mg/kg cyclophosphamide, a dose which destroys ~50% of PMF reserve, by evaluation of ovulation, mating and pregnancy rates. Reproductive potential of treated mice was not affected compared with controls despite the significant loss of PMF. Our results indicate that reproductive performance is not an accurate parameter for assessing ovarian injury. Rather, histological counting of PMF number more directly reflects the damage caused by chemotherapy to the ovary. This method can be used as a sensitive, inexpensive tool to gauge the damage to fertility caused by new chemotherapy agents or protocols.
Key words: chemotherapy/mouse/ovarian failure/primordial follicles/reproduction
To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Carmely, D. Meirow, A. Peretz, M. Albeck, B. Bartoov, and B. Sredni Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice Hum. Reprod., June 1, 2009; 24(6): 1322 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Maman, K. Prokopis, J. Levron, A. Carmely, J. Dor, and D. Meirow Does controlled ovarian stimulation prior to chemotherapy increase primordial follicle loss and diminish ovarian reserve? An animal study Hum. Reprod., January 1, 2009; 24(1): 206 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Cocco, C Sardu, P Gallo, R Capra, M. Amato, M Trojano, A Uccelli, M. Marrosu, and the FEMIMS group* Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study Multiple Sclerosis, November 1, 2008; 14(9): 1225 - 1233. [Abstract] [PDF]
|
|
|
|
 |
|
 L A Gonzalez, G McGwin Jr, S Duran, G J Pons-Estel, M Apte, L M Vila, J D Reveille, G S Alarcon, and for the LUMINA Study Group Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII) Ann Rheum Dis, August 1, 2008; 67(8): 1170 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Oktay, M. Sonmezer, O. Oktem, K. Fox, G. Emons, and H. Bang Absence of Conclusive Evidence for the Safety and Efficacy of Gonadotropin-Releasing Hormone Analogue Treatment in Protecting Against Chemotherapy-Induced Gonadal Injury Oncologist, September 1, 2007; 12(9): 1055 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Meirow, J. Dor, B. Kaufman, A. Shrim, J. Rabinovici, E. Schiff, H. Raanani, J. Levron, and E. Fridman Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury Hum. Reprod., June 1, 2007; 22(6): 1626 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Donnez, B. Martinez-Madrid, P. Jadoul, A. Van Langendonckt, D. Demylle, and M.-M. Dolmans Ovarian tissue cryopreservation and transplantation: a review Hum. Reprod. Update, September 1, 2006; 12(5): 519 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sonmezer and K. Oktay Fertility preservation in young women undergoing breast cancer therapy. Oncologist, May 1, 2006; 11(5): 422 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Desmeules and P. J. Devine Characterizing the Ovotoxicity of Cyclophosphamide Metabolites on Cultured Mouse Ovaries Toxicol. Sci., April 1, 2006; 90(2): 500 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Roberts and K. Oktay Fertility Preservation: A Comprehensive Approach to the Young Woman With Cancer J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 57 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lutchman Singh, M. Davies, and R. Chatterjee Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing Hum. Reprod. Update, January 1, 2005; 11(1): 69 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus Lupus, December 1, 2004; 13(12): 887 - 890. [PDF]
|
|
|
|
|
|
K. Oktay, M. Sonmezer, and O. Oktem 'Ovarian cryopreservation versus ovarian suppression by GnRH analogues: primum non nocere': Reply Hum. Reprod., July 1, 2004; 19(7): 1681 - 1683. [Full Text] [PDF]
|
|
|
|
|
|
D. Meirow, G. Assad, J. Dor, and J. Rabinovici The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice Hum. Reprod., June 1, 2004; 19(6): 1294 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sonmezer and K. Oktay Fertility preservation in female patients Hum. Reprod. Update, May 1, 2004; 10(3): 251 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Letterie Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure Hum. Reprod., April 1, 2004; 19(4): 831 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Larsen, J. Muller, K. Schmiegelow, C. Rechnitzer, and A. N. Andersen Reduced Ovarian Function in Long-Term Survivors of Radiation- and Chemotherapy-Treated Childhood Cancer J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5307 - 5314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.C. Larsen, J. Muller, C. Rechnitzer, K. Schmiegelow, and A.N. Andersen Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l Hum. Reprod., February 1, 2003; 18(2): 417 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Meirow, M. Epstein, H. Lewis, D. Nugent, and R.G. Gosden Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations Hum. Reprod., April 1, 2001; 16(4): 632 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Linch, R. G. Gosden, T. Tulandi, S.-L. Tan, and S. L. Hancock Hodgkin's Lymphoma: Choice of Therapy and Late Complications Hematology, January 1, 2000; 2000(1): 205 - 221. [Abstract] [Full Text] [PDF]
|
|